title: Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.
abstract: BACKGROUND
  Biliary tract cancers are uncommon tumors with a poor prognosis and most patients present with invasive and inoperable disease at diagnosis. Chemotherapy represents a palliative treatment, with poor response rates and a median survival of less than 6 months. Oxaliplatin and gemcitabine have shown an interesting activity as single agents in this group of patients.
  
  
  METHODS
  We carried out a multicenter phase II study to evaluate the efficacy and safety of combined oxaliplatin and gemcitabine in locally advanced and metastatic biliary tract carcinoma. The schedule of chemotherapy included oxaliplatin 100 mg/m(2) on day 1 and gemcitabine 1000 mg/m(2) on days 1 and 8, every 21 days.
  
  
  RESULTS
  All the 24 patients were evaluable for response and toxicity. According to RECIST criteria we observed one complete response and 11 partial responses for an overall response rate of 50%. Overall survival for all the patients on study was 12 months (range 2-30). According to WHO criteria, three patients (12.5%) suffered grade 3 neutropenia and three patients (12.5%) grade 3 thrombocytopenia. Only two patients (8%) suffered grade 3 neuropathy.
  
  
  CONCLUSIONS
  Oxaliplatin and gemcitabine chemotherapy seems to be effective with a favorable safety profile in first-line chemotherapy of advanced biliary tract cancers.
authors.affiliation: Department of Medicine, Oncology Unit, Azienda Ospedaliera Giovanni Paolo II Sciacca (AG), Palermo, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Verderame
authors.forename: A
authors.initials: A
authors.lastname: Russo
authors.forename: R
authors.initials: R
authors.lastname: Di Leo
authors.forename: G
authors.initials: G
authors.lastname: Badalamenti
authors.forename: D
authors.initials: D
authors.lastname: Santangelo
authors.forename: G
authors.initials: G
authors.lastname: Cicero
authors.forename: M R
authors.initials: MR
authors.lastname: Valerio
authors.forename: G
authors.initials: G
authors.lastname: Gulotta
authors.forename: G
authors.initials: G
authors.lastname: Tomasello
authors.forename: N
authors.initials: N
authors.lastname: Gebbia
authors.forename: F
authors.initials: F
authors.lastname: Fulfaro
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001650:Bile Duct Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005260:Female; D005706:Gallbladder Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D015996:Survival Rate; D000093542:Gemcitabine
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000093542:Gemcitabine